How is the Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market Poised for Growth: Trends and Opportunities Through 2034
Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!
How has the Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics market grown over the years?
In recent times, the market size for therapeutics and diagnostics of exocrine pancreatic insufficiency (EPI) has seen significant growth. The market is projected to increase from a value of $5.69 billion in 2024 to $6.17 billion in 2025, boasting a compound annual growth rate (CAGR) of 8.4%. The expansion during the historical period is due to factors such as increased incidence of root causes, advancements in diagnostic technology, evolution in pharmaceutical techniques, and improved global healthcare accessibility.
What Is the forecasted market size and growth rate for the exocrine pancreatic insufficiency (epi) therapeutics and diagnostics market?
The market for therapeutics and diagnostics related to exocrine pancreatic insufficiency (EPI) is projected to experience substantial growth in the coming years. The market size is anticipated to rise to $8.32 billion by 2029, with a compound annual growth rate (CAGR) of 7.8%. The upswing during the forecast period can be linked to developments in telemedicine and remote monitoring, data analytics and AI, as well as improvements in patient education/support and changes in regulatory and reimbursement policies. Key trends envisioned for this period encompass personalized treatment strategies, the introduction of new therapies, less invasive diagnostic methods, and cooperative care models.
Get your exocrine pancreatic insufficiency (epi) therapeutics and diagnostics market report here!
What are the major factors driving growth in the exocrine pancreatic insufficiency (epi) therapeutics and diagnostics market?
As diabetes prevalence rises, it’s predicted to fuel advancements in the exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market. Diabetes is a long-term metabolic disorder associated with elevated blood sugar levels (hyperglycemia) over an extended duration. This is primarily due to the body not producing sufficient insulin or not being able to effectively utilize the insulin it does create. EPI therapy, which incorporates pancreatic enzyme replacement therapy (PERT), can enhance nutrient absorption in diabetic patients and those with EPI and can also better control blood sugar levels in diabetic individuals. For instance, The National Health Service (NHS England) reported in June 2024 that the number of individuals in England identified as pre-diabetic by the NHS had risen by 18% to 3,615,330 in 2023, up from 3,065,825 in 2022. Notably, among the under-40 age group, the number increased almost 25%, up from 173,166 in 2022 to 216,440 in 2023. Therefore, the rising diabetes prevalence is stimulating the exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market’s growth. Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market Driver: An Uptick in Gastrointestinal Disorders Expected to Boost Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics
What key areas define the segmentation of the global exocrine pancreatic insufficiency (epi) therapeutics and diagnostics Market?
The exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market covered in this report is segmented –
1) By Therapies: Nutritional Management, Pancreatic Enzyme Replacement Therapy (PERT), Lifestyle Modifications Approach
2) By Diagnostics: Blood Tests, Magnetic Resonance Imaging (MRI), Endoscopic Ultra-Sonography (EUS), Computerized Tomography (CT) Scanning
3) By Drug Type: Generic, Branded
4) By Distribution Channel: Direct Tender, Retail Pharmacy , Third-Party Distributor, Other Distribution Channels
5) By End User: Hospitals, Specialty Clinics, Homecare, Diagnostic Center, Research And Academic Institutes, Other End Users
Subsegments:
1) By Nutritional Management: Dietary Modifications, Nutritional Supplements
2) By Pancreatic Enzyme Replacement Therapy (PERT): Capsule Formulations, Tablet Formulations, Powder Formulations
3) By Lifestyle Modifications Approach: Weight Management, Physical Activity Recommendations, Smoking Cessation Programs
Get your free sample now – explore exclusive market insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=12992&type=smp
What are the top market players propelling the growth of the exocrine pancreatic insufficiency (epi) therapeutics and diagnostics industry?
Major companies operating in the exocrine pancreatic insufficiency (epi) therapeutics and diagnostics market are Pfizer Inc., Merck & Co. Inc., Janssen Pharmaceuticals Inc., AbbVie Inc., Novartis AG, Sanofi S.A., AstraZeneca PLC, Abott Laboratories, Medtronic PLC, Solvay S.A., Laboratory Corporation of America Holdings (Labcorp), Organon group of companies Metagenics LLC, Allergan PLC, Chiesi Farmaceutici S.p.A., Codexis Inc., Nordmark Arzneimittel GmbH & Co. KG, ChiRhoClin Inc., Digestive Care Inc., Alcresta Therapeutics Inc., Vivus Inc., Cilian AG, Bioserv Diagnostics Gmbh, Anthera Pharmaceuticals Inc., Aptalis Pharma Inc., First Wave BioPharma Inc., EagleBiosciences Inc., ScheBo Biotech AG.
What are the key trends shaping the future of the exocrine pancreatic insufficiency (epi) therapeutics and diagnostics market?
Key corporations in the Exocrine Pancreatic Insufficiency (EPI) therapeutics and diagnostics market are leveraging strategic partnerships to augment tech integration and widen their market presence. Strategic partnerships often involve two or more organizations pooling their resources, competencies, and endeavors to realize shared aims. For instance, in February 2023, a noteworthy partnership was formed between Codexis, Inc., a US-based protein engineering company, and Nestlé Health Science, a nutrition science company from Switzerland. They released preliminary results from their initial clinical trial of CDX-7108, a therapy under investigation for the treatment of EPI. These phase 1 trial findings could lay the foundation for additional studies that may considerably enhance treatment choices for EPI patients.
Unlock exclusive market insights – purchase your research report now for a swift delivery!
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=12992
What regions are dominating the exocrine pancreatic insufficiency (epi) therapeutics and diagnostics market growth?
North America was the largest region in the exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market in 2024. The regions covered in exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
Browse Through More Similar Reports By The Business Research Company:
Gastric Volvulus Treatment Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/gastric-volvulus-treatment-global-market-report
Inflammatory Bowel Disease Treatment Global Market Report 2024
Digestive Health Supplements Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/digestive-health-supplements-global-market-report
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Found this article helpful? Share it on:
